
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The Sr. Manager, HCP Marketing will lead the development and execution of HCP marketing strategies to support Neurocrine’s growth objectives in CAH. This role focuses on engaging CAH centers of excellence, adrenal specialists, high-volume endocrinologists, and key opinion leaders (KOLs) through insights-driven, brand-aligned initiatives.
Key responsibilities include developing disease state education and promotional materials, enabling the sales force and leading brand presence at major conferences and congresses. The role requires strong cross-functional collaboration to ensure seamless execution of strategy and tactics, working closely with Sales, Sales Training, Market Research, Regulatory, Legal, Medical Affairs, Managed Markets, and agency partners.
This individual will drive the creation of marketing programs targeting priority HCP segments, including COEs and high-volume endocrinologists, while supporting broader brand-building efforts and growth initiatives in CAH. They will also lead scientific engagement activities and ensure alignment between marketing and sales through an effective omnichannel approach to HCP engagement.
The ideal candidate brings experience in rare diseases, preferably in endocrinology, pediatrics, or genetic conditions, along with a strong background in HCP marketing and brand launches. They understand the importance of aligning HCP and patient strategies and have demonstrated success in digital and omnichannel campaigns, including microtargeting and next-best-action approaches. A collaborative leader, this individual fosters alignment, drives cross-functional engagement, and builds momentum behind the brand’s mission.
#LI-MV1
Neurocrine Biosciences is an EEO/Disability/Vets employer.
We are committed to building a workplace of belonging, respect, and empowerment, and we recognize there are a variety of ways to meet our requirements. We are looking for the best candidate for the job and encourage you to apply even if your experience or qualifications don’t line up to exactly what we have outlined in the job description.
The annual base salary we reasonably expect to pay is $158,100.00-$216,000.00. Individual pay decisions depend on various factors, such as primary work location, complexity and responsibility of role, job duties/requirements, and relevant experience and skills. In addition, this position offers an annual bonus with a target of 30% of the earned base salary and eligibility to participate in our equity based long term incentive program. Benefits offered include a retirement savings plan (with company match), paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage in accordance with the terms and conditions of the applicable plans.

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.
Review our Community Guidelines: https://bit.ly/NeurocrineLinkedInGuidelines
*in collaboration with AbbVie